Long-Term Withdrawal of Anticoagulation and Antiplatelet Therapy in a HeartMate 3 Left Ventricular Assist Device

A 73-year-old male with end-stage heart failure underwent insertion of the HeartMate 3 (Abbott, North Chicago, IL, USA) device. Systemic anticoagulation and antiplatelets were discontinued for 52 days due to postoperative bleeding. After hemorrhage resolution, we restarted warfarin monotherapy targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Menchaca, Kristina, Ostos Perez, Catherine A, Draguljevic, Nemanja, Paciletti, Jennifer, Ghumman, Waqas, Faber, Cristiano, Mirza, Sajid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiac/Thoracic/Vascular Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462652/
https://www.ncbi.nlm.nih.gov/pubmed/36111326
http://dx.doi.org/10.7759/cureus.28779
Descripción
Sumario:A 73-year-old male with end-stage heart failure underwent insertion of the HeartMate 3 (Abbott, North Chicago, IL, USA) device. Systemic anticoagulation and antiplatelets were discontinued for 52 days due to postoperative bleeding. After hemorrhage resolution, we restarted warfarin monotherapy targeting an international normalized ratio of 1.8-2.5. Eight months later, there are no reports of pump thrombosis, thromboembolism, and bleeding.

Ejemplares similares